Ulcerative colitis is a chronic idiopathic inflammatory bowel disease of the gastrointestinal tract that affects the mucosal lining of the colon.
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) of the gastrointestinal tract that affects the mucosal lining of the colon. It commonly occurs in people aged between 15 years and 30 years. Ulcerative colitis is one of the two major types of IBD along with Crohn’s disease. Unlike Crohn’s disease, which can affect any part of the gastrointestinal tract, ulcerative colitis characteristically involves only the large bowel. The actual cause of the disease is still unidentified. However, the available information suggests that it may be the result of an over reactive immune response to normal bacteria and other substances in the gastrointestinal tract. The prominent symptoms of ulcerative colitis are abdominal pain and bloody diarrhea due to inflammation and the development of open sores (ulcers) in the large intestine (colon) and rectum. Other symptoms of ulcerative colitis include abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and fatigue. Severe complications of ulcerative colitis include hemorrhage, colon rupture, and the possible development of colon cancer. About 20% of people with ulcerative colitis have a family member with the disease or with Crohn’s disease, which is also a type of IBD. There is no known cure for ulcerative colitis till now. However, therapies are available that may significantly reduce the signs and symptoms of ulcerative colitis and even bring about a long-term remission.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2185
The global ulcerative colitis therapeutics market is expected to expand substantially due to a rise in the prevalence of ulcerative colitis and increase in research and development to develop innovative treatment for ulcerative colitis. However, patent expiry of drugs and stringent government rules and regulations for approval of biosimilars are likely to constrain ulcerative colitis therapeutics market growth. Unmet needs in the treatment of ulcerative colitis are estimated to provide lucrative growth opportunities for the ulcerative colitis therapeutics market.
The global ulcerative colitis therapeutics market can be segmented based on drug class, distribution channel, and geography. Based on drug class, the global ulcerative colitis therapeutics market can be divided into aminosalicylates (sulfasalazine, mesalamine, and others), corticosteroids (prednisone, methylprednisolone), immunomodulators, antibiotics (ampicillin, ciprofloxacin), and others. In terms of distribution channels, the ulcerative colitis therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online sales.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2185
Based on geography, the ulcerative colitis therapeutics market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The ulcerative colitis therapeutics market in each geography is sub-segmented into specific countries such as the U.S., Canada, the U.K., Germany, Brazil, China, India, and GCC countries. North America dominated the global ulcerative colitis therapeutics market because of the prevalence of ulcerative colitis and increase in demand for innovative medical technology. In the U.S., ulcerative colitis affects approximately 250,000 to 500,000 individuals, with an incidence of 8 to 12 per 100,000 persons annually, which has remained constant over the past five decades. Asia Pacific is expected to be a highly attractive region of the over the forecast period, due to an increase in health care awareness and rise in demand for advanced medical technology.
Pre Book Ulcerative Colitis Therapeutics Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=2185<ype=S
Key players operating in ulcerative colitis therapeutics market are AbbVie, Takeda Pharmaceuticals, Roche, Teva Pharmaceutical Industries Ltd., Johnson and Johnson, AstraZeneca, Shire Pharmaceuticals, Pfizer, Merck, and other prominent players. In order to gain a competitive advantage in the industry, the major players are actively involved in various growth strategies. Collaborations, agreements, partnerships, and new product launches are some of the important strategies applied by market players. In May 2018, Takeda Pharmaceutical Company Limited and Shire plc signed an agreement for the development of innovative gastrointestinal disease products.
More Trending Reports by Transparency Market Research:
Aseptic Transfer System Market: Safe manufacture of pharmaceutical drugs has triggered the demand for aseptic transfer systems amidst the ongoing COVID-19 (coronavirus) crisis. Companies in the aseptic transfer system market are taking advantage of the COVID-19 situation to increase the availability of products. As such, there is a growing awareness about sterile and particle-free manufacture of pharmaceutical drugs.
Iron Deficiency Anemia Treatment Market: Iron metabolism and anemia may play an important role in multiple organ dysfunction during the ongoing COVID-19 pandemic. Patients with iron deficiency are more susceptible to coronavirus. Hence, companies in the iron deficiency anemia treatment market have increased their output capacities to avoid supply shocks for medications in pharmacies and hospitals.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/